Arcellx (ACLX) Shares Encouraging Data on Latest Laboratory Study
On February 12, Qize Ding from Rothschild & Co Redburn downgraded the rating on Arcellx Incorporated (NASDAQ:ACLX) from Buy to Neutral.
Arcellx Inc. (ACLX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Paradigm Biocapital Advisors Senai Asefaw | 5,724,016 | $373,205,843 | +24% | 9.53% |
| 2. | Vestal Point Capital Ryan Wilder | 2,925,000 | $190,710,000 | +134% | 6.48% |
| 3. | SR One Capital Simeon George | 2,346,630 | $153,000,276 | 21.66% | |
| 4. | Citadel Investment Group Ken Griffin | 1,500,223 | $97,814,539 | +47% | 0.01% |
| 5. | Perceptive Advisors Joseph Edelman | 1,466,071 | $95,587,829 | -41% | 1.7% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $16.00 | 312,500 | $5,000,000.00 | 6,745,262 | 2022-06-21 | Filing | |
| $15.00 | 1,600,000 | $24,000,000.00 | 2,033,196 | 2022-02-08 | Filing | |
| $15.00 | 66,667 | $1,000,005.00 | 3,466,811 | 2022-02-08 | Filing | |
| $15.00 | 1,583,333 | $23,749,995.00 | 6,432,762 | 2022-02-08 | Filing | |
| $15.00 | 1,600,000 | $24,000,000.00 | 2,033,196 | 2022-02-08 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $69.38 | 100 | $6,938.00 | 45,157 | 2026-02-19 | Filing | |
| $68.57 | 5,405 | $370,634.90 | 45,257 | 2026-02-19 | Filing | |
| $67.73 | 2,879 | $194,994.96 | 50,662 | 2026-02-19 | Filing | |
| $70.01 | 4,150 | $290,551.88 | 53,541 | 2026-02-17 | Filing | |
| $69.21 | 7,141 | $494,230.75 | 57,691 | 2026-02-17 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 6,720,803 | $438,196,356 | 22.64% | |
| 2. | 4,081,519 | $266,115,040 | 0% | |
| 3. | 3,563,728 | $232,355,097 | 0.01% | |
| 4. | 3,548,787 | $231,380,928 | 0% | |
| 5. | 3,045,262 | $198,551,082 | 10.12% |
News See All
17 Biotechnology Stocks with More Than 50% Upside
2025 was a year characterized by both challenges and opportunities for the biotechnology sector.
Arcellx (ACLX) Declined Despite Positive Clinical Trial Results
Baron Funds, an investment management company, released its fourth-quarter investor letter for the “Baron Health Care Fund”. A copy of the letter can be downloaded here.
UBS Initiates Coverage of Arcellx With Bullish Outlook as Biotech Fundamentals Inflect
Arcellx Inc. (NASDAQ:ACLX) is one of the best high short interest stocks with biggest upside potential.
11 Best High Short Interest Stocks With Biggest Upside Potential
On January 27, Sherry Paul, a senior portfolio manager at Morgan Stanley, appeared on CNBC's 'Closing Bell' to discuss whether more volatility is ahead, following a volatile week in the market.
Arcellx, Inc. (ACLX) Makes Progress on Multiple Myeloma Treatment
Arcellx Inc. (NASDAQ:ACLX) is one of the best biotech stocks to buy according to Wall Street analysts.
15 Best Biotech Stocks to Buy According to Wall Street Analysts
The biotech sector has been a disaster for investors over the past five years going by a 14% decline compared to an 86% gain for the S&P 500 over the same period.
CAR-Therapy Keeps Analyst Confidence in Arcellx (ACLX) High Ahead of the ASH Meeting
On November 25, 2025, Arcellx, Inc. (NASDAQ:ACLX) saw Morgan Stanley’s Judah Frommer reiterate a “Buy” rating.
12 Oversold Global Stocks to Invest In
Appearing in an interview with CNBC on November 21, 2025, David Katz of Matrix Asset Advisors called widespread weakness a potential entry point, saying that the current correction is “much closer to...
Hedge Fund Resource Center Billionaire Hedge Funds
